ViSci – Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert

TEL-AVIV (July 24, 2017) – BioLight Life Sciences Ltd. (TASE: BOLT) , an emerging global ophthalmic company focused on the discovery, development and commercialization of ophthalmic products and product candidates, announced today  successful results from its glaucoma insert VS101  Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure for a 12-week period, with a favorable safety profile.

Link to complete article 

Link to Newsroom

Comments are closed.